Log in
HMG-CoA reductase inhibitor (statin)

Rosuvastatin

Rosuvastatin is a synthetic, high-potency HMG-CoA reductase inhibitor (statin) used primarily to lower LDL cholesterol and reduce cardiovascular morbidity and mortality. It is one of the most potent statins available, achieving greater LDL reduction per milligram than most other agents in its class. The most testable fact: rosuvastatin is hydrophilic, which may reduce its penetration into non-hepatic tissues and potentially lower the risk of certain muscle-related adverse effects compared to lipophilic statins.

Practice questionsHigh-yield facts
Drug classHMG-CoA reductase inhibitor (statin)
MechanismCompetitively inhibits HMG-CoA reductase, reducing hepatic cholesterol synthesis
Main usesHyperlipidemia, primary and secondary prevention of cardiovascular disease
Key adverse effectMyopathy, elevated liver enzymes, new-onset diabetes
7 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Rosuvastatin competitively and reversibly inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and critical step in cholesterol production.

By blocking cholesterol synthesis, hepatocytes upregulate surface LDL receptors to capture circulating LDL particles, thereby lowering plasma LDL cholesterol. Rosuvastatin also modestly raises HDL cholesterol and lowers triglycerides, though the primary therapeutic effect is LDL reduction.

Rosuvastatin is hydrophilic, unlike lipophilic statins such as atorvastatin and simvastatin. This property limits its distribution into peripheral tissues and concentrates its action in the liver, which may contribute to a different adverse effect profile. The drug demonstrates high first-pass hepatic extraction and selectivity for hepatic HMG-CoA reductase.

High-yield for exams
  • Rosuvastatin is a high-potency HMG-CoA reductase inhibitor (statin) used to lower LDL cholesterol and reduce cardiovascular events.
  • Hydrophilic statin with preferential hepatic uptake via OATP1B1 transporter; minimal CYP3A4 metabolism reduces drug-drug interactions.
  • Key adverse effects: myopathy/rhabdomyolysis (rare), hepatotoxicity, new-onset diabetes, and myalgia (common).
  • Contraindicated in pregnancy (category X), active liver disease, and concomitant cyclosporine use.
  • Asian populations and patients with SLCO1B1 polymorphisms may have higher plasma levels; start at lower strengths.
  • Monitor CK only if muscle symptoms develop; routine monitoring is not recommended in asymptomatic patients.
  • Gemfibrozil significantly increases myopathy risk; avoid concomitant use or use lowest statin strength with close monitoring.
  • JUPITER trial showed rosuvastatin reduces cardiovascular events in primary prevention even in patients with normal LDL but elevated hs-CRP.

Indications

Rosuvastatin is indicated for:

  • Primary hyperlipidemia and mixed dyslipidemia: to reduce elevated LDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B, and to increase HDL cholesterol
  • Hypertriglyceridemia: as adjunct to diet
  • Primary dysbetalipoproteinemia (Type III hyperlipoproteinemia): as adjunct to diet
  • Homozygous familial hypercholesterolemia: as adjunct to other lipid-lowering treatments or when such treatments are unavailable
  • Primary prevention of cardiovascular disease: in patients with elevated cardiovascular risk (e.g., age, hypertension, low HDL, smoking, family history) but without clinically evident coronary heart disease
  • Secondary prevention: in patients with established atherosclerotic cardiovascular disease (prior MI, stroke, stable or unstable angina, peripheral arterial disease) to reduce the risk of MI, stroke, revascularization procedures, and cardiovascular death
  • Slowing progression of atherosclerosis: as adjunct to diet

Rosuvastatin is typically initiated alongside lifestyle modification (diet, exercise, weight management) and used for long-term lipid control and cardiovascular risk reduction.

Pharmacokinetics

Absorption

Rosuvastatin is absorbed in the gastrointestinal tract with a bioavailability of approximately 20% due to significant first-pass hepatic extraction. Peak plasma concentrations occur about 3–5 hours after oral administration. Food does not significantly affect absorption, so the drug may be taken with or without meals.

Distribution

Rosuvastatin is highly bound to plasma proteins, primarily albumin (approximately 90%). Its hydrophilic nature limits tissue penetration compared to lipophilic statins, resulting in preferential hepatic uptake via the OATP1B1 transporter. Volume of distribution is relatively small.

Metabolism

Rosuvastatin undergoes limited hepatic metabolism. Approximately 10% is metabolized, primarily via CYP2C9 (a minor pathway), with minimal involvement of CYP3A4. The majority of the drug is excreted unchanged. This contrasts with many other statins that are extensively metabolized by CYP3A4, making rosuvastatin less susceptible to CYP3A4-mediated drug interactions.

Excretion

Approximately 90% of rosuvastatin is excreted unchanged in the feces (via biliary and intestinal secretion), and about 10% is recovered in urine. The elimination half-life is approximately 19 hours, allowing once-daily administration. Renal impairment and certain genetic polymorphisms (e.g., SLCO1B1 variants affecting OATP1B1) can increase plasma concentrations, requiring careful monitoring or reduced initiation.

Special populations

Asian populations may have higher plasma concentrations due to genetic differences in hepatic uptake transporters. Severe renal impairment (CrCl <30 mL/min) increases exposure and requires starting at lower strengths. Hepatic impairment is a contraindication.

Adverse effects

Rosuvastatin is generally well tolerated, but several adverse effects require monitoring.

Common adverse effects

  • Headache
  • Myalgia: muscle aches without CK elevation, reported in 2–10% of patients
  • Nausea, abdominal pain, constipation
  • Asthenia (weakness)

Serious adverse effects

  • Myopathy and rhabdomyolysis: rare but potentially life-threatening. Defined as muscle symptoms with creatine kinase (CK) elevation >10 times the upper limit of normal. Rhabdomyolysis can lead to acute renal failure due to myoglobinuria. Risk is higher with concomitant use of fibrates (especially gemfibrozil), cyclosporine, or in the setting of hypothyroidism, renal impairment, or advanced age. Patients should be instructed to report unexplained muscle pain, tenderness, or weakness immediately.
  • Hepatotoxicity: elevated transaminases (ALT, AST) occur in <1% of patients. Persistent elevations >3 times the upper limit of normal warrant discontinuation. Routine monitoring of liver enzymes is recommended at baseline and as clinically indicated.
  • New-onset diabetes mellitus: statins, including rosuvastatin, are associated with a modest increased risk of developing type 2 diabetes, particularly in patients with pre-existing risk factors (metabolic syndrome, impaired fasting glucose). The cardiovascular benefits generally outweigh this risk.
  • Proteinuria and hematuria: dipstick-positive proteinuria has been observed, particularly at higher strengths, though it is rarely associated with progressive renal disease.
  • Immune-mediated necrotizing myopathy (IMNM): very rare, characterized by proximal muscle weakness and elevated CK that persists despite statin discontinuation; anti-HMGCR antibodies may be present.

Other considerations

  • Cognitive effects: rare reports of memory loss or confusion, generally reversible upon discontinuation.
  • Interstitial lung disease: very rare but reported with statins.

Contraindications and warnings

Absolute contraindications

  • Active liver disease or unexplained persistent elevations of serum transaminases
  • Pregnancy: rosuvastatin is FDA pregnancy category X (contraindicated). Cholesterol and cholesterol derivatives are essential for fetal development, and statins reduce cholesterol synthesis. Women of childbearing potential should use effective contraception.
  • Lactation: the drug may be excreted in breast milk and is contraindicated during breastfeeding.
  • Hypersensitivity to rosuvastatin or any component of the formulation

Warnings and precautions

  • Myopathy risk factors: initiate at lower strengths and monitor closely in patients with predisposing factors (advanced age >65 years, hypothyroidism, renal impairment, concomitant fibrates or cyclosporine, personal or family history of hereditary muscular disorders, prior statin intolerance).
  • Asian ancestry: patients of Asian descent may have higher plasma concentrations; consider starting at lower strengths.
  • Renal impairment: severe impairment (CrCl <30 mL/min) increases drug exposure; lower starting strengths are recommended, and the highest strengths are contraindicated.
  • Hypothyroidism: must be adequately treated before initiating statin therapy, as hypothyroidism increases myopathy risk.
  • Alcohol use: heavy alcohol consumption may increase hepatotoxicity risk; use with caution.
  • Hemorrhagic stroke: some post-marketing data suggest a possible increased risk in patients with prior hemorrhagic stroke; assess benefit-risk individually.
  • Proteinuria: routine urinalysis is not required but may be considered in high-risk patients.

Drug interactions

Rosuvastatin has fewer CYP450-mediated interactions than many statins, but important interactions exist due to its reliance on hepatic uptake transporters.

Major interactions (increased rosuvastatin levels or myopathy risk)

  • Cyclosporine: dramatically increases rosuvastatin exposure via inhibition of OATP1B1 and other transporters. Concomitant use is contraindicated or requires significant reduction in rosuvastatin strength.
  • Gemfibrozil: increases rosuvastatin levels and myopathy risk; avoid concomitant use if possible. If used together, limit rosuvastatin strength and monitor closely.
  • Protease inhibitors (e.g., atazanavir/ritonavir, lopinavir/ritonavir): inhibit OATP1B1 and increase rosuvastatin concentrations; lower rosuvastatin strengths and close monitoring are required.
  • Fenofibrate: less interaction than gemfibrozil but still increases myopathy risk when combined with statins; use lowest effective statin strength.

Moderate interactions

  • Antacids (aluminum and magnesium hydroxide): reduce rosuvastatin absorption by approximately 50%; administer rosuvastatin at least 2 hours before antacids.
  • Warfarin: rosuvastatin may potentiate anticoagulant effect; monitor INR when initiating or adjusting statin therapy.
  • Oral contraceptives: rosuvastatin modestly increases ethinyl estradiol and norgestrel levels; not clinically significant in most cases.
  • Ezetimibe: no significant pharmacokinetic interaction, and combination therapy is commonly used for additional LDL lowering.

Minimal CYP3A4 interaction

Unlike atorvastatin, simvastatin, and lovastatin, rosuvastatin is not significantly metabolized by CYP3A4. Therefore, it does not have major interactions with CYP3A4 inhibitors (e.g., clarithromycin, grapefruit juice, azole antifungals) or inducers, offering an advantage in patients on complex medication regimens.

Clinical pearls

  • Potency: Rosuvastatin is one of the most potent statins for LDL reduction; lower strengths of rosuvastatin achieve comparable LDL lowering to higher strengths of other statins.
  • Hydrophilicity: Its hydrophilic nature concentrates hepatic action and may reduce peripheral tissue penetration, potentially lowering the risk of muscle-related side effects compared to lipophilic statins, though this remains debated.
  • Time of administration: Unlike some short-acting statins, rosuvastatin can be taken at any time of day due to its long half-life, improving adherence.
  • CK monitoring: Routine CK monitoring is not recommended in asymptomatic patients; check CK only if muscle symptoms develop. Baseline CK measurement is reasonable in high-risk patients.
  • Statin intolerance: For patients with prior myalgia on other statins, consider switching to rosuvastatin at a lower strength or alternate-day dosing, as individual tolerance varies.
  • Combination therapy: Often combined with ezetimibe for patients requiring additional LDL reduction beyond statin monotherapy, or with PCSK9 inhibitors in very high-risk or statin-intolerant patients.
  • Cardiovascular outcomes: Large trials (e.g., JUPITER, METEOR) have demonstrated rosuvastatin reduces cardiovascular events in both primary and secondary prevention settings.
  • Genetic considerations: SLCO1B1 polymorphisms increase rosuvastatin exposure; patients of Asian descent or those with known variants may require lower starting strengths.
  • Adherence: Emphasize that statins are long-term medications; many cardiovascular benefits accrue over years of consistent use.

Practice questions

1. A 58-year-old man with type 2 diabetes and hypertension presents for a routine follow-up. His LDL cholesterol is 145 mg/dL despite lifestyle modifications. He has no history of cardiovascular disease. His physician prescribes rosuvastatin for primary prevention. Three weeks later, the patient reports new-onset bilateral thigh pain and weakness. Laboratory tests show a creatine kinase level of 2,800 U/L (normal <200 U/L). What is the most appropriate next step in management?

Answer: A. This patient has statin-induced myopathy with significantly elevated CK (>10 times normal) and muscle symptoms. Immediate discontinuation of rosuvastatin is required to prevent progression to rhabdomyolysis and acute renal failure. Continuing the statin at any strength, switching to another statin without a washout period, or adding supplements while continuing therapy are inappropriate and dangerous. While checking TSH is reasonable (hypothyroidism increases myopathy risk), the statin must be stopped first.

2. A 62-year-old woman with a history of myocardial infarction is on rosuvastatin for secondary prevention. She is also taking gemfibrozil for hypertriglyceridemia. Her primary care physician is concerned about drug interactions. Which of the following best explains the increased risk of adverse effects with this combination?

Answer: B. Gemfibrozil increases rosuvastatin plasma concentrations through inhibition of hepatic uptake transporters and glucuronidation pathways, significantly raising the risk of myopathy and rhabdomyolysis. This combination should generally be avoided. Rosuvastatin is not significantly metabolized by CYP3A4, making option A incorrect. Gemfibrozil does not enhance renal excretion; in fact, it increases statin levels. While both drugs can affect the liver, the primary concern is the pharmacokinetic interaction leading to elevated statin exposure and muscle toxicity.

3. A 45-year-old Asian woman with familial hypercholesterolemia is started on rosuvastatin. Her physician notes that patients of Asian descent may require adjusted initial therapy. What is the primary reason for this consideration?

Answer: C. Patients of Asian descent have a higher prevalence of genetic polymorphisms in the SLCO1B1 gene, which encodes the OATP1B1 hepatic uptake transporter. These variants reduce hepatic uptake of rosuvastatin, leading to higher plasma concentrations and increased risk of adverse effects. Lower starting strengths are therefore recommended. Rosuvastatin is not significantly metabolized by CYP3A4, and there is no evidence that Asian populations have inherently lower LDL levels or higher dietary cholesterol that would affect statin dosing. While hypothyroidism prevalence varies, the primary concern is the pharmacogenetic difference in drug transporter function.

Frequently asked questions

How does rosuvastatin work?

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. By blocking cholesterol production, the liver upregulates LDL receptors on its surface to capture circulating LDL particles from the blood, thereby lowering plasma LDL cholesterol. It also modestly raises HDL cholesterol and reduces triglycerides. Rosuvastatin is hydrophilic, which concentrates its action in the liver and limits peripheral tissue penetration.

What are the side effects of rosuvastatin?

Common side effects include headache, myalgia (muscle aches), nausea, constipation, and abdominal pain. Serious but rare adverse effects include myopathy and rhabdomyolysis (severe muscle breakdown with elevated creatine kinase), hepatotoxicity (elevated liver enzymes), and new-onset diabetes mellitus. Patients should report unexplained muscle pain, tenderness, or weakness immediately. Routine monitoring of liver enzymes and CK (if symptomatic) is recommended.

Is rosuvastatin safe during pregnancy?

No, rosuvastatin is contraindicated during pregnancy (FDA category X). Cholesterol and its derivatives are essential for fetal development, and statins inhibit cholesterol synthesis, which may cause fetal harm. Women of childbearing potential should use effective contraception while taking rosuvastatin, and the drug should be discontinued immediately if pregnancy is detected. It is also contraindicated during breastfeeding.

Rosuvastatin vs atorvastatin — what is the difference?

Both are potent statins, but rosuvastatin is hydrophilic and primarily excreted unchanged, with minimal CYP3A4 metabolism, resulting in fewer drug-drug interactions. Atorvastatin is lipophilic and extensively metabolized by CYP3A4, making it more susceptible to interactions with CYP3A4 inhibitors like clarithromycin or grapefruit juice. Rosuvastatin achieves similar or greater LDL reduction at lower milligram strengths. Both are effective for primary and secondary cardiovascular prevention, and choice often depends on patient-specific factors, tolerability, and interaction profile.

Can rosuvastatin cause muscle pain?

Yes, myalgia (muscle pain without CK elevation) is a common side effect, reported in 2–10% of patients. Serious myopathy with elevated creatine kinase and rhabdomyolysis is rare but can occur, especially with higher strengths, concomitant fibrates, renal impairment, or hypothyroidism. Patients experiencing unexplained muscle pain, tenderness, or weakness should contact their physician immediately. CK levels should be checked if symptoms develop, and the drug should be discontinued if myopathy is confirmed.

Conditions it is used for

HyperlipidemiaHypercholesterolemiaMixed dyslipidemiaHypertriglyceridemiaFamilial hypercholesterolemiaAtherosclerotic cardiovascular diseasePrimary prevention of cardiovascular diseaseSecondary prevention of cardiovascular disease
AtorvastatinSimvastatinPravastatinLovastatinFluvastatinPitavastatinEzetimibeEvolocumab

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: C10AA07

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.